Longevity & Anti-Aging Peptides

Telomeres — the protective caps on chromosome ends — shorten with each cell division, eventually triggering cellular senescence. Epithalon (Epitalon, AEDG peptide) is a synthetic tetrapeptide studied by Russian researcher Vladimir Khavinson for its potential to activate telomerase, the enzyme that extends telomeres. Cell culture studies (Khavinson et al., 2003) showed telomerase activation and extended replicative lifespan in human fibroblasts. Rodent studies reported extended lifespan and improved biomarkers. However, no Western randomized controlled trials have been published, and all major clinical data comes from Russian-language publications, limiting independent verification.

Senescent cells — cells that have permanently stopped dividing but resist apoptosis — accumulate with age and secrete pro-inflammatory factors (the SASP: senescence-associated secretory phenotype) that damage surrounding tissue. FOXO4-DRI is an experimental D-retro-inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells, re-enabling apoptosis. In aged mice, FOXO4-DRI restored fur density, renal function, and physical fitness (Baar et al., Cell 2017). Human trials have not been conducted. The D-retro-inverso design confers exceptional protease resistance but makes manufacturing expensive.

Mitochondrial dysfunction is a hallmark of aging. SS-31 (Elamipretide) selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and restoring electron transport chain efficiency. It has advanced to phase III clinical trials for Barth syndrome and mitochondrial myopathy, with preliminary data in heart failure and age-related macular degeneration. MOTS-c is a mitochondrial-derived peptide encoded in the mitochondrial genome that activates AMPK signaling, promoting glucose uptake and fatty acid oxidation. Humanin is another mitochondrial-derived peptide with cytoprotective effects against oxidative stress and apoptosis.

SS-31/Elamipretide has the strongest evidence in this class with multiple clinical trials. Epithalon has extensive but unverified Russian clinical data. FOXO4-DRI has a compelling single preclinical study. MOTS-c and Humanin are in early research stages. The Khavinson bioregulator peptides (Epithalon, Cartalax, Livagen, Pinealon, etc.) represent a body of work that is scientifically interesting but difficult to evaluate due to limited Western peer review. Researchers should approach longevity claims with particular skepticism given the extraordinary nature of the claims and the preliminary state of the evidence.